The EFMC’s communication team has been established to help promoting Medicinal Chemistry and Chemical Biology in Europe and around the globe, with the aim to create a shared network, and inspire young future scientists.
Please get in touch with us, and share contents or suggestions: email@example.com
Kristina Goncharenko works in the business development team at SpiroChem, fine chemicals company based in Basel, Switzerland. Her main goal is to support medicinal chemists around the globe in designing drugs of tomorrow. She completed her PhD at the University of Basel in a diverse field: by combining biochemistry, biology and chemistry her project was focused on understanding the mechanism of a novel enzyme called sulfoxide synthase. Kristina is an active member of the Swiss Chemical Society and helps to strengthen the communication between pharmaceutical industry and young chemists. She believes that having a close network of medicinal chemists and chemical biologists will support innovation in science.
Nadia Ahmad obtained her MSci. in Chemistry with Medicinal Chemistry at Imperial College London, before moving to the University of Nottingham to undertake her PhD in natural product synthesis with Professor Nigel Simpkins. This was proceeded by a Postdoctoral Fellowship at the Institute of Cancer Research, London, working under the tutelage of Professor Keith Jones.
She then joined Takeda at its Cambridge site in the UK, during which time she undertook a six-month secondment at the Takeda San Diego site, working on CNS disorders and inflammation. She then moved to Eli Lilly and was fortunate enough to be able to continue fulfilling her passion for neuroscience, working primarily on GPCRs. Nadia joined CRL in 2019 from Vertex Pharmaceuticals where she worked on ion channel and enzyme targets in the areas of neuropathic pain and neurodegenerative disorders, and cancer. She is a Group Leader in medicinal chemistry with responsibility for leading multi-disciplinary teams all the way from Hit ID to pre-clinical candidate.
Chiara Borsari is a senior postdoctoral fellow and co-lecturer at the University of Basel. Her research is focused on the development of kinase inhibitors, with a particular attention on PI3K and mTOR signalling pathway. After the successful discovery and optimization of reversible lead compounds, she is currently leading a variety of projects on covalent inhibitors, PROTACs and bifunctional compounds. After research visits at the NHRF in Athens and the State University of New York at Albany, USA, she obtained her Ph.D. from the University of Modena and Reggio Emilia (Italy) in 2017.
She is also keen on communicating her science to the public. In 2019, her short movie “Life in Colour”, explaining the advancements in cancer research, has won the Jury Prize at the Exposure Science Film Hackathon. She has joined the EFMC communication team to boost the awareness of the importance of Medicinal Chemistry in science.
Piia Bartos is a post-doctoral researcher currently working at University of Eastern Finland. She got her PhD in pharmaceutical chemistry in 2015 from the same university where she studied sirtuin inhibitors. The increased activity of sirtuins is associated with many health benefits and longer lifespan, but in her project she was only able to find compounds to inhibit their function. She had no intention to make people sick and live shorter lives, though, as also sirtuin inhibitors could be useful in the treatment of some health problems, such as diabetes or cancer. She moved slightly away from her comfort zone of drug design and designed a variety of enzymes during her first post-doctoral position in Czech Republic, as obviously it is not challenging enough to design small molecules. After this international experience, she got back to University of Eastern Finland to use her newly learned computational simulation skills to understands the mechanisms of protein-RNA interaction. Piia joined the Communication Team to promote the slightly bizarre field of medicinal chemistry to everyone.
Laia Josa-Culleré is a Marie Curie postdoctoral researcher at the Institute for Advanced Chemistry of Catalonia (IQAC-CSIC) in Barcelona. After finishing her Bachelor in Chemistry at the University of Barcelona, she obtained a Master’s degree from the University of Cambridge and a PhD at the University of Oxford, where she stayed for her first postdoc. There, she led a drug discovery project aimed at finding novel small molecules that could differentiate acute myeloid leukemia (AML) cells in a wide range of patient populations. Her current research focuses on the development of a new therapy against cancer stem cells, using external light to control drug selectivity.
She joined the YSN to help strengthen the network of medicinal chemists in Europe, and to foster communication both within the network and to the general public.
Etienne J. Donckele performed his undergraduate research with Prof. Dr. Barry M. Trost at Stanford University and a one-year placement in medicinal chemistry at the Broad Institute of MIT and Harvard working for Dr. Lisa Marcaurelle and in collaboration with Prof. Dr. Eric Jacobsen and Prof. Dr. Stuart Schreiber at Harvard University. In 2016, he received his Ph.D. in organic chemistry at the ETH Zürich under the supervision of Prof. Dr. François Diederich. In parallel of his studies, he has been the president of the Behringer Simon Lecture within the same university (2014-2015). For his postdoctoral work, he held a Swiss National Science Foundation fellowship at Caltech, where he worked in the laboratory of Prof. Dr. Brian M. Stoltz on completing the total synthesis of (+)-Kopsihainanine A. In 2017, Etienne gained experience across multiples phases of drug discovery throughout Philochem AG (a swiss subsidiary of the Philogen group) first as a research scientist before taking on the role of Deputy Head of Chemistry. He focused on the development of the DNA-encoded chemical library platfor (e.g., library design, new DNA-compatible reactions) and was responsible for the hit to lead validation against a repertoire of protein targets in immuno-oncology. Since mid-2021, he has joined Monte Rosa Therapeutics as senior scientist in medicinal chemistry for the discovery of new molecular glue degraders, a novel class of small molecule drugs, for the delivery of pioneering cancer therapies. Etienne is a named inventor on 3 patent applications and has authored 18 scientific publications.
Caroline Lanthier is a third year PhD student in medicinal chemistry at CERMN (Centre d’Etudes et de Recherche sur le Médicament de Normandie) in Caen France under the supervision of Prof. Christophe Rochais. Her research focus on the development of pleiotropric drug of interest in Alzheimer’s Disease. During her pharmaceutical study in Lille, she was in charge of the communication for the local pharmacy student association for two years. She joined the EFMC communication team to help promoting the network and the field of medicinal chemistry.
Brieuc Matagne studied communication, marketing and political sciences at the University of Louvain, Belgium. Interested by the event planning world for a long time, he joined LD Organisation in 2014 as Conference Manager. In mid-2015, he started managing the Administrative Secretariat of the EFMC as part of his mission at LD Organisation. Since then, he is working behind the scene in helping running the daily business of the EFMC together with the Executive Committee Members. Lone non-scientist in this team of talented ones, he is using his expertise in communication and planning to assist the team in their mission to increase the EFMC visibility and brand awareness.
Michele Mari is Assistant Professor (RTD-B) in Medicinal Chemistry at University of Urbino Carlo Bo, He achieved his Ph.D. in Chemical and Pharmaceutical Sciences from the same university working on the strategic indole functionalization for the synthesis of tryptophan containing alkaloids and biologically active tryptamines. He spent 9 months at ETH Zurich as visiting researcher working on the total synthesis of proteins. In september 2017 he founded GLUOS (innovative Start up and University Spin off on the synthesis of molecules for medical devices) with some colleagues and he is actually the President of the Board of Directors of the company. He is also member of the organizing committee of the European School of Medicinal Chemistry, and he is active locally in spreading the importance of soft skills and entrepreneurship vision. The driving force that makes him so active is an infinite passion for Science.
Marta Piquero is a medicinal chemist, working as a postdoctoral researcher at the University of Basel, in the group of Prof. D. Gillingham. Her current research is focus on the discovery of novel protein degradation mechanism for oncological application. In 2020, she got her PhD at the Complutense University of Madrid (UCM) under the supervision of Prof. Jose Carlos Menéndez and Pilar Lopez-Alvarado. Her research was focused on the development of novel theranostic and multitarget compounds against neurodegenerative diseases. During this period, she carried out a predoctoral secondment in the group of Professor Dario Neri at ETH (Zürich, Switzerland). Marta joined the EFMC communication team because she belives that building a network of scientists, sharing ideas is the best way to do science.
Matic Proj is a PhD student at the Faculty of Pharmacy, University of Ljubljana, Slovenia. His research focuses on the design and evaluation of fragment libraries for the discovery of potential enzyme inhibitors. His scientific work is interdisciplinary and it includes techniques of biochemistry, cheminformatics, molecular modelling, chemical analysis and synthetic organic chemistry. During his studies, Matic was active in a national Pharmaceutical Students’ association and worked as Public Relations Representative. As one of the youngest team members with a great passion for science, he brings his ideas, computer and social media skills. He joined the team in March 2019 to gain new knowledge and experience while promoting the field of Medicinal Chemistry and facilitating communication.
Filipa Ramilo Gomes is a PhD student in Medicinal Chemistry at Instituto Superior Técnico, University of Lisbon, Portugal under the supervision of Prof. M. Matilde Marques (MedChemTrain PhD Programme). She received her master’s degree in Pharmaceutical Sciences at University of Beira Interior, Portugal. Before starting the PhD, she participated in multiple international projects related with Pharmaceutical Sciences and Medicinal Chemistry.
Her PhD project is focusing on cancer epigenetics, particularly the design, synthesis and biological evaluation of new EZH2 inhibitors. Filipa worked as PhD visiting student in the Computational Aided Drug Design field at University of Vienna and Inte:Ligand GmbH, Vienna, Austria. Then, Filipa moved to Hamburg, Germany, to work as PhD visiting student at Fraunhofer Institute- ScreeningPort, where she evaluated the biological profile of prospective new drugs.
Filipa joined the Communication Team and Young Scientist Network because she believes that only by working together with the best scientists, sharing ideas, ambitions and dreams, it is possible to contribute to address society’s health needs.
Clemens Zwergel is currently an Assistant Professor (RTD-A) at the Sapienza University of Rome. In the last years he proved to be a true European citizen: he moved after his license to practise as Pharmacist from his country of origin (Germany) to Exter (UK) for a Diploma in Pharmaceutical Sciences. Before moving to Italy, he was then a MarieCurie fellow in France (Metz) where he obtained his EuroPhD within the RedCat network. Since 2010, his main research interest lies mainly in the design and synthesis of analogues of natural compounds as well as modulators of epigenetic enzymes with potential applications in cancer, neurodegenerative, metabolic, and infectious diseases resulting in more than 50 publications. Communication and divulging science are very important aspects for a researcher, thus I would like to increase the visibility of Medicinal Chemistry and the EFMC to the scientific community as well as the general public as well as strengthen the European collaborations together with the other team members.
Luc Van Hijfte holds a PhD degree in Chemistry from Gent University (1984, Belgium) with Prof M Vandewalle, and finalized his academic training by a two-year post-doctoral stay at UCSB with Prof RD Little. He started his industrial career as a medicinal chemist at Merrell Dow in 1986 in Strasbourg, France, where he progressed to head of the medicinal chemistry by the time the site had become part of Sanofi in 1998. In 2002 he moved to Janssen, J&J, first as Research Director of their R&D site in Val de Reuil, France, before taking on the role of Senior Director, Head of Medicinal Chemistry EU, at Janssen Research & Development, with responsibility for European-based medicinal chemistry, analytical technologies, and ADMET.
During this tenure, Luc was privileged to contribute to several successful projects, with numerous programs entering into clinical development in the areas of neurosciences, oncology, and infectious diseases. In 2012 Dr Van Hijfte became CSO of NovAliX, Illkirch, France, before moving in 2017 to his actual position of Sr VP Medicinal Chemistry at Symeres, where he oversees a team of approx. 80 chemists executing medicinal chemistry activities for clients worldwide.
Dr Van Hijfte has been the Vice-President of the French Medicinal Chemistry Society (SCT) in 2015-16, President of the SCT 2017-18, and is currently member of the Executive Committee of the EFMC. In 2018, he has been elected and named member of the “Académie Nationale de Pharmacie” in France, for his multiple contributions to pharmaceutical developments.